局限性前列腺癌4次立体定向放疗的I期剂量递增试验
这项I期剂量递增试验评估了局限性前列腺癌患者接受4次立体定向体部放疗(SBRT)的安全性与耐受性,分3个剂量水平(8 Gy、8.5 Gy、9 Gy/次),每水平入组9例低危或中危患者。各剂量水平均未出现剂量限制性毒性(DLT),故将第3水平(36 Gy/4次,中间休息2天)定为推荐剂量(RD),3年生化控制率为90.3%。
要点
- 每水平9例低危或中危患者,3个剂量水平均未出现DLT。
- 第3水平36 Gy/4次(休息2天)被定为II期推荐剂量。
- 毒性多为1级,泌尿生殖系毒性较胃肠道毒性常见。
核心结论
- 36 Gy分4次、中间休息2天的SBRT方案对局限性前列腺癌可耐受且结果令人鼓舞。
- 正在开展II期试验以确认该治疗的疗效与毒性。
研究设计与样本
- I期剂量递增试验,分3个剂量水平:8 Gy、8.5 Gy、9 Gy/次,每水平入组9例。
- 处方剂量覆盖至少95%的计划靶体积,全部患者接受图像引导调强放疗。
- DLT定义为急性3级及以上毒性;MTD定义为≥30%患者出现DLT的剂量水平;RD为MTD下一剂量水平,若第3水平无DLT则第3水平为RD。
主要发现
- 所有患者均完成方案治疗,各剂量水平均无患者出现DLT。
- 第1-3水平的中位随访时间分别为48.9个月、42.6个月和18.4个月。
- 大多数毒性为1级,泌尿生殖系毒性较胃肠道毒性常见。
- 3年生化控制率为90.3%。
关键数值与推荐
- DLT定义为急性毒性3级或更高。
- MTD定义为≥30%患者出现DLT的剂量水平。
- RD定义为MTD下一剂量水平;若第3水平无DLT,则第3水平为RD。
- 第3水平(9 Gy×4次)被指定为II期研究的RD,总剂量36 Gy,中间休息2天。
临床怎么用
- 对于低危或中危局限性前列腺癌,36 Gy/4次、休息2天的SBRT方案可作为II期研究推荐剂量。
- 治疗中应关注泌尿生殖系毒性,尽管多为1级。
局限性
- 样本量小,每剂量水平仅9例。
- 随访时间有限,第3水平中位随访仅18.4个月。
- 仅纳入低危或中危患者,结果不能外推至高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report results from our phase I dose-escalation study of stereotactic body radiotherapy (SBRT) using 4 fractions for patients with localized prostate cancer. MATERIALS & METHODS: Fraction sizes of 8 Gy, 8.5 Gy, and 9 Gy were defined as levels 1, 2, and 3. The prescribed dose was delivered to at least 95% of the planning target volume. Image-guided, intensity-modulated radiotherapy was delivered to all patients. Dose-limiting toxicity (DLT) was defined as acute toxicity of Grade 3 or higher. The maximum tolerated dose (MTD) was defined as the level at which ≥30% of patients showed DLT. The recommended dose (RD) was defined to be one dose level below the MTD. If no patients at level 3 showed DLT, level 3 was defined as the recommended dose (RD). RESULTS: Nine patients were enrolled in each level. All patients were low or intermediate risk. Median durations of follow-up for patients at levels 1-3 were 48.9 months, 42.6 months, and 18.4 months, respectively. Protocol treatment was completed for all patients. No patient showed DLT at each dose level. Level 3 was therefore designated as the RD for the phase II study. Although most toxicities were Grade 1, genitourinary toxicity was common compared to gastrointestinal toxicity. Three-year biochemical control rate was 90.3%. CONCLUSION: The dose level of 36 Gy in 4 fractions with a 2-day break was tolerable and highly encouraging for SBRT of localized prostate cancer. The phase II trial to confirm the efficacy and toxicity of this treatment is now on going. TRIAL REGISTRATION: UMIN, UMIN000010236 . Registered 13 March 2013.
引用
- Kainuma T, Kawakami S, Tsumura H, et al. A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer. Radiat Oncol. 2019. PMID: 31477122. doi:10.1186/s13014-019-1369-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。